There were no deviations observed from clinical characteristics of patients, including ISS staging (I, II and III), prior transplantation, type of myeloma (IgG, IgA, and IgM in addition to light chains) and the length of PFS in both studies (Table 4). The gene discussed is CD79A; the disease is plasma cell myeloma.